tiprankstipranks
Advertisement
Advertisement

ATOS Stock Latest News

Jason McCarthy Reiterates Buy on Endoxifen Developer, Lifting 12-Month Price Target to $20 on Strong ER+ Breast Cancer Data and Pipeline Expansion
RatingsJason McCarthy Reiterates Buy on Endoxifen Developer, Lifting 12-Month Price Target to $20 on Strong ER+ Breast Cancer Data and Pipeline Expansion
2d ago
ATOS
Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year
PremiumThe Fly
Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year
22d ago
ATOS
Atossa Therapeutics Shareholders Approve Proposals at 2026 Meeting
PremiumCompany Announcements
Atossa Therapeutics Shareholders Approve Proposals at 2026 Meeting
23d ago
8K
ATOS
Atossa Therapeutics’ Endoxifen shows breast cancer risk prevention in trial
PremiumThe Fly
Atossa Therapeutics’ Endoxifen shows breast cancer risk prevention in trial
24d ago
ATOS
Atossa Therapeutics says FDA grants RPD to (Z)-endoxifen to treat MAS
PremiumThe Fly
Atossa Therapeutics says FDA grants RPD to (Z)-endoxifen to treat MAS
27d ago
ATOS
Atossa: Patent De‑Risking and Endoxifen Franchise Optionality Support Buy Rating and Upside to Target Price
PremiumRatingsAtossa: Patent De‑Risking and Endoxifen Franchise Optionality Support Buy Rating and Upside to Target Price
1M ago
ATOS
Atossa Therapeutics Resolves Endoxifen Patent Disputes, Clarifies Rights
Premium
Company Announcements
Atossa Therapeutics Resolves Endoxifen Patent Disputes, Clarifies Rights
1M ago
8K
ATOS
Atossa Therapeutics target adjusted to $25 from $7 at H.C. Wainwright
Premium
The Fly
Atossa Therapeutics target adjusted to $25 from $7 at H.C. Wainwright
2M ago
ATOS
Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)
PremiumThe Fly
Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)
2M ago
ATOS
Atossa Therapeutics announces addition of two biopharma executives to team
PremiumThe Fly
Atossa Therapeutics announces addition of two biopharma executives to team
2M ago
ATOS
VTI ETF Inflows Hold Steady Despite AI Sell-Off – 2/24/26
PremiumMarket News
VTI ETF Inflows Hold Steady Despite AI Sell-Off – 2/24/26
3M ago
L
CLB
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/23/26
PremiumMarket News
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/23/26
3M ago
CLB
IMA
Atossa Therapeutics Launches New $50 Million ATM Program
PremiumCompany AnnouncementsAtossa Therapeutics Launches New $50 Million ATM Program
3M ago
8K
ATOS
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/20/26
Premium
Market News
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/20/26
3M ago
L
CLB
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/19/26
Premium
Market News
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/19/26
3M ago
L
CLB
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk
PremiumCompany Announcements
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk
3M ago
8K
ATOS
Atossa Therapeutics price target lowered to $10 from $35 at Craig-Hallum
PremiumThe Fly
Atossa Therapeutics price target lowered to $10 from $35 at Craig-Hallum
4M ago
ATOS
Atossa Therapeutics Issues 2026 Outlook and Strategic Update
PremiumCompany Announcements
Atossa Therapeutics Issues 2026 Outlook and Strategic Update
4M ago
8K
ATOS
Atossa Therapeutics: Strategic Endoxifen Opportunity in DMD and PRV Creates Buy-Rated Upside at Disconnected Valuation
PremiumRatings
Atossa Therapeutics: Strategic Endoxifen Opportunity in DMD and PRV Creates Buy-Rated Upside at Disconnected Valuation
4M ago
ATOS
Upcoming Stock Splits This Week (February 2 to February 6) – Stay Invested
PremiumMarket NewsUpcoming Stock Splits This Week (February 2 to February 6) – Stay Invested
4M ago
PBM
AREB
Atossa Genetics trading halted, news pending
Premium
The Fly
Atossa Genetics trading halted, news pending
4M ago
ATOS
Atossa Therapeutics Sets 15-for-1 Reverse Stock Split
Premium
Company Announcements
Atossa Therapeutics Sets 15-for-1 Reverse Stock Split
4M ago
8K
ATOS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >